NO20061252L - Doseringsplan for ERBB2 antikreftmidler - Google Patents

Doseringsplan for ERBB2 antikreftmidler

Info

Publication number
NO20061252L
NO20061252L NO20061252A NO20061252A NO20061252L NO 20061252 L NO20061252 L NO 20061252L NO 20061252 A NO20061252 A NO 20061252A NO 20061252 A NO20061252 A NO 20061252A NO 20061252 L NO20061252 L NO 20061252L
Authority
NO
Norway
Prior art keywords
erbb2
mammal
inhibitor
anticancer agents
dosage schedule
Prior art date
Application number
NO20061252A
Other languages
English (en)
Norwegian (no)
Inventor
Richard Damian Connell
Samit Kumar Bhattacharya
James Dale Moyer
Jitesh Pranlal Jani
Dennis Alan Noe
Stefanus Johannes Steyn
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO20061252L publication Critical patent/NO20061252L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20061252A 2003-08-18 2006-03-17 Doseringsplan for ERBB2 antikreftmidler NO20061252L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49591903P 2003-08-18 2003-08-18
PCT/IB2004/002580 WO2005016347A1 (en) 2003-08-18 2004-08-06 Dosing schedule for erbb2 anticancer agents

Publications (1)

Publication Number Publication Date
NO20061252L true NO20061252L (no) 2006-05-16

Family

ID=34193358

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061252A NO20061252L (no) 2003-08-18 2006-03-17 Doseringsplan for ERBB2 antikreftmidler

Country Status (18)

Country Link
US (1) US20050119288A1 (enExample)
EP (1) EP1658080A1 (enExample)
JP (1) JP2007502807A (enExample)
KR (2) KR20060037447A (enExample)
CN (1) CN1838959A (enExample)
AR (1) AR045268A1 (enExample)
AU (1) AU2004264726A1 (enExample)
BR (1) BRPI0413745A (enExample)
CA (1) CA2536140A1 (enExample)
CO (1) CO5670356A2 (enExample)
IL (1) IL173127A0 (enExample)
MX (1) MXPA06001989A (enExample)
NO (1) NO20061252L (enExample)
RU (1) RU2328287C2 (enExample)
SG (1) SG135193A1 (enExample)
TW (1) TW200522966A (enExample)
WO (1) WO2005016347A1 (enExample)
ZA (1) ZA200600517B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2472341C (en) 2002-02-01 2011-06-21 Ariad Gene Therapeutics, Inc. Phosphorus-containing compounds & uses thereof
US8505468B2 (en) * 2002-11-19 2013-08-13 Sharp Kabushiki Kaisha Substrate accommodating tray
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
WO2005016346A1 (en) 2003-08-14 2005-02-24 Array Biopharma Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
UA83252C2 (uk) 2003-09-19 2008-06-25 Астразенека Аб Похідні хіназоліну, спосіб їх одержання (варіанти), фармацевтична композиція на їх основі, проміжна сполука
RS52119B (sr) * 2004-05-06 2012-08-31 Warner-Lambert Company Llc 4-fenilamino-hinazolin-6-il-amidi
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
CA2610661A1 (en) * 2005-06-03 2006-12-07 Pfizer Products Inc. Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
CA2609251A1 (en) * 2005-06-16 2006-12-28 Myriad Genetics, Inc. Pharmaceutical compositions and use thereof
US20080219977A1 (en) * 2005-07-27 2008-09-11 Isaiah Josh Fidler Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
WO2007059106A2 (en) * 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of mntor inhibitor to treat patients with cancer
PT2090575E (pt) * 2005-11-15 2011-06-06 Array Biopharma Inc Inibidores de erbb
EP2163563A1 (en) * 2006-03-31 2010-03-17 Massachusetts Institute of Technology Treatment of tumors expressing mutant EGF receptors
CN101415411A (zh) * 2006-04-05 2009-04-22 诺瓦提斯公司 用于治疗癌症的治疗剂组合
CN101583347A (zh) 2006-11-14 2009-11-18 阿里亚德医药股份有限公司 口服制剂
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
WO2008124824A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Dosages and methods for the treatment of cancer
EP2144888A4 (en) * 2007-04-10 2012-10-03 Myrexis Inc METHODS OF TREATING CANCER
AU2008236993A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Method of treating brain cancer
NZ580867A (en) * 2007-04-10 2011-02-25 Myriad Pharmaceuticals Inc Method of treating melanoma
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
CA3006428A1 (en) * 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
WO2009137714A2 (en) * 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
US20100087459A1 (en) * 2008-08-26 2010-04-08 Leonid Metsger Forms of lapatinib compounds and processes for the preparation thereof
JP5624114B2 (ja) * 2009-03-20 2014-11-12 ジェネンテック， インコーポレイテッド 抗ｈｅｒ抗体
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
CN110564604B (zh) * 2014-01-31 2023-09-29 凸版印刷株式会社 液滴的形成方法、生物分子分析方法及生物分子分析试剂盒
HK1259311A1 (zh) 2015-10-28 2019-11-29 Tva (Abc), Llc Sstr靶向綴合物及其顆粒和製劑

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA932522B (en) * 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
ES2161290T3 (es) * 1995-03-30 2001-12-01 Pfizer Derivados de quinazolina.
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
NZ522568A (en) * 2000-06-22 2004-12-24 Pfizer Prod Inc Substituted bicyclic derivatives for the treatment of abnormal cell growth
KR20040065259A (ko) * 2001-12-12 2004-07-21 화이자 프로덕츠 인크. Ｅ-2-메톡시-ｎ-(3-(4-(3-메틸-피리딘-3-일옥시)-페닐아미노)-퀴나졸린-6-일)-알릴)-아세트아미드의 염 형태, 그의제조 방법 및 그의 암 치료에 있어서의 용도
PL373848A1 (en) * 2001-12-12 2005-09-19 Pfizer Products Inc. Quinazoline derivatives for the treatment of abnormal cell growth
AU2003291394B2 (en) * 2002-11-20 2009-06-25 Array Biopharma, Inc Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
RU2005119172A (ru) * 2002-12-18 2006-01-20 Пфайзер Продактс Инк. (Us) Производные 4-анилинхиназолина для лечения патологического роста клеток

Also Published As

Publication number Publication date
CN1838959A (zh) 2006-09-27
TW200522966A (en) 2005-07-16
AR045268A1 (es) 2005-10-19
BRPI0413745A (pt) 2006-10-24
US20050119288A1 (en) 2005-06-02
KR20080014144A (ko) 2008-02-13
RU2328287C2 (ru) 2008-07-10
WO2005016347A1 (en) 2005-02-24
SG135193A1 (en) 2007-09-28
KR20060037447A (ko) 2006-05-03
RU2006102125A (ru) 2007-09-27
IL173127A0 (en) 2006-06-11
MXPA06001989A (es) 2006-05-17
JP2007502807A (ja) 2007-02-15
CO5670356A2 (es) 2006-08-31
EP1658080A1 (en) 2006-05-24
CA2536140A1 (en) 2005-02-24
AU2004264726A1 (en) 2005-02-24
ZA200600517B (en) 2007-02-28

Similar Documents

Publication Publication Date Title
NO20061252L (no) Doseringsplan for ERBB2 antikreftmidler
ZA202109010B (en) Compounds and methods for the treatment of covid-19
NO20050204L (no) Kombinasjoner av legemidler for behandling av neoplasmer
RU2010133480A (ru) Лечение метастатической стадии рака предстательной железы дегареликсом
RU2012111823A (ru) Ферментная заместительная терапия с увеличением дозы для лечения недостаточности кислой сфингомиелиназы
TW200500355A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
BR0314699A (pt) Composto, composição e métodos para o tratamento da dor e para inibição da função vr1 em uma célula
SG10201810806UA (en) Interlaced method for treating cancer or a precancerous condition
UA81625C2 (ru) Применение ротиготина для трансепикутального лечения синдрома уставших ног
NZ744233A (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
IL307516A (en) Tremor treatment
BR0014166A (pt) Método de utilização de inibidores de reabsorção de serotonina seletivo de rápido ataque para tratamento de disfunção sexual
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
TW200639159A (en) Treatment of pain
MX2007004955A (es) Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente.
TW200719903A (en) Compositions for the treatment of neoplasms
MX2010002679A (es) Derivados de 4-oxoquinolina deuterados para el tratamiento de la infeccion por el virus de inmunodeficiencia humana.
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.
NO20063320L (no) Anvendelse av gaboxadol for behandling av insomni
TW200635609A (en) Novel pharmaceutical composition containing at least one dolastatin 10 derivative
MXPA05006378A (es) Compuestos esteroides con actividad anti-tumoral.
BR0014447A (pt) Derivados de piperidina como inibidores da reabsorção
WO2025049967A3 (en) Inhibition of pcbp2 to enhance efficacy of immunotherapy
MX2023008796A (es) Métodos para el tratamiento del trastorno del habla en niños.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application